Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Capucine Baldini

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Patient Education and Counseling|September 20, 2024
Health literacy and the use of digital tools in older patients with cancer and their younger counterparts: A multicenter, nationwide studyElena Paillaud, Angéline Galvin, Solène Doublet, et al.
JCO Precision Oncology|October 31, 2022
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine OncologyPatricia Martin-Romano, Laura Mezquita, Antoine Hollebecque, et al.
JCO Precision Oncology|May 30, 2024
Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING TrialJulieta Rodriguez, Capucine Baldini, Arnaud Bayle, et al.
Cancers|September 9, 2022
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a TrialJohn Hilton, Mihaela Cristea, Sophie Postel-Vinay, et al.
Neurology|September 30, 2022
In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of <i>IDH</i>-Mutant Diffuse Gliomas: The <i>IDASPE</i> Prospective StudyAnna Luisa Di Stefano, Lucia Nichelli, Giulia Berzero, et al.
Current Oncology Reports|July 27, 2024
Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive ReviewLaurent Mathiot, Capucine Baldini, Octave Letissier, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2024
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive reviewArthur Géraud, Thomas Hueso, Ariane Laparra, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2026
Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP studyMatthieu Delaye, Paul Matte, Adrien Mouren, et al.
Brain Communications|October 15, 2021
Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelaeLéo Plaçais, Jean-Marie Michot, Stéphane Champiat, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2022
Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patientsLambros Tselikas, Antoine Dardenne, Thierry de Baere, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Patient Education and Counseling|September 20, 2024
Health literacy and the use of digital tools in older patients with cancer and their younger counterparts: A multicenter, nationwide studyElena Paillaud, Angéline Galvin, Solène Doublet, et al.
JCO Precision Oncology|October 31, 2022
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine OncologyPatricia Martin-Romano, Laura Mezquita, Antoine Hollebecque, et al.
JCO Precision Oncology|May 30, 2024
Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING TrialJulieta Rodriguez, Capucine Baldini, Arnaud Bayle, et al.
Cancers|September 9, 2022
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a TrialJohn Hilton, Mihaela Cristea, Sophie Postel-Vinay, et al.
Neurology|September 30, 2022
In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of <i>IDH</i>-Mutant Diffuse Gliomas: The <i>IDASPE</i> Prospective StudyAnna Luisa Di Stefano, Lucia Nichelli, Giulia Berzero, et al.
Current Oncology Reports|July 27, 2024
Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive ReviewLaurent Mathiot, Capucine Baldini, Octave Letissier, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2024
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive reviewArthur Géraud, Thomas Hueso, Ariane Laparra, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2026
Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP studyMatthieu Delaye, Paul Matte, Adrien Mouren, et al.
Brain Communications|October 15, 2021
Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelaeLéo Plaçais, Jean-Marie Michot, Stéphane Champiat, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2022
Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patientsLambros Tselikas, Antoine Dardenne, Thierry de Baere, et al.
Pageof 11